Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ: CPRX · Real-Time Price · USD
21.08
+0.52 (2.53%)
At close: Aug 22, 2025, 4:00 PM
21.00
-0.08 (-0.38%)
After-hours: Aug 22, 2025, 7:59 PM EDT
Catalyst Pharmaceuticals Employees
Catalyst Pharmaceuticals had 181 employees as of December 31, 2024. The number of employees increased by 14 or 8.38% compared to the previous year.
Employees
181
Change (1Y)
14
Growth (1Y)
8.38%
Revenue / Employee
$3,085,630
Profits / Employee
$1,152,845
Market Cap
2.58B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 181 | 14 | 8.38% |
Dec 31, 2023 | 167 | 85 | 103.66% |
Dec 31, 2022 | 82 | 6 | 7.89% |
Dec 31, 2021 | 76 | 2 | 2.70% |
Dec 31, 2020 | 74 | -2 | -2.63% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CPRX News
- 15 days ago - Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update - GlobeNewsWire
- 16 days ago - Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC) - GlobeNewsWire
- 18 days ago - Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors - GlobeNewsWire
- 4 weeks ago - Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewsWire
- 2 months ago - Top 3 Health Care Stocks You'll Regret Missing This Quarter - Benzinga
- 2 months ago - Strong Inflows Make Catalyst Stock an Outlier - FXEmpire
- 2 months ago - 20 stocks you should avoid — no matter how well the market does - Market Watch